专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013164512A3 COMPOSITION FOR USE IN THE TREATMENT AND/OR PREVENTION OF OCULAR INFLAMMATION, OXIDATIVE STRESS AND NEOVASCULARIZATION 审中-公开
标题翻译：用于治疗和/或预防眼部炎症，氧化应激和新生血管的组合物
公开(公告)号：WO2013164512A3
公开(公告)日：2014-03-20
申请号：PCT/ES2013070279
申请日：2013-05-06
申请人： UNIV VALLADOLID , ALLERGAN INC
发明人： GONZALEZ GARCIA MARIA JESUS , CALONGE CANO MARGARITA , ENRIQUEZ DE SALAMANCA ALADRO AMALIA , STERN MICHAEL E , ABENGOZAR VELA ANTONIO
IPC分类号： A61K31/352 , A61K31/05 , A61K45/06 , A61L12/14 , A61P27/02 , C11D3/00 , C11D3/48
CPC分类号： A61K31/352 , A61K31/05 , A61K45/06 , C11D3/0078 , C11D3/48 , C11D7/261 , C11D7/267 , A61K2300/00
摘要： The invention relates to the use of quercetin (QCT) or of a composition comprising QCT and at least another polyphenolic compound, preferably resveratrol (RES), for the treatment and/or prevention of lesions or diseases associated with inflammation, oxidative stress and/or ocular neovascularization, preferably of the anterior segment, more preferably of the ocular surface and even more preferably of the corneal epithelium. The invention also relates to the use of QCT and said composition as an antimicrobial, antioxidant and anti-inflammatory agent in solutions for cleaning and maintaining contact lenses.
摘要翻译：本发明涉及槲皮素（QCT）或包含QCT和至少另一种多酚化合物（优选白藜芦醇（RES））的组合物用于治疗和/或预防与炎症，氧化应激和/或相关的病变或疾病的用途眼部新血管形成，优选前段，更优选眼表面，甚至更优选角膜上皮。本发明还涉及QCT和所述组合物在用于清洁和保持隐形眼镜的溶液中作为抗微生物剂，抗氧化剂和抗炎剂的用途。

2. 发明申请

WO2006055417A3 METHODS FOR THE THERAPEUTIC USE OF CYCLOSPORINE COMPONENTS 审中-公开
标题翻译：环孢素组分的治疗方法
公开(公告)号：WO2006055417A3
公开(公告)日：2006-08-24
申请号：PCT/US2005040926
申请日：2005-11-11
申请人： ALLERGAN INC , STERN MICHAEL E , POWER DAVID
发明人： STERN MICHAEL E , POWER DAVID
IPC分类号： A61K38/13
CPC分类号： A61K38/13
摘要： Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
摘要翻译：公开了治疗具有各种病症的人或动物的方法，其包括施用环孢菌素组分。治疗的病症包括口干综合征，疣状黄瘤，嗜酸性粒细胞粘液囊肿，口腔粘膜下纤维变性，口腔痣，口腔黏膜癌，泌尿系泌尿系膜炎，外阴阴道炎，幽门螺杆菌感染，十二指肠溃疡，消化性溃疡，影响子宫和阑尾炎的病症。

3. 发明申请

WO2011159881A3 IL-10 AND METHODS OF TREATING OCULAR AND OTHER DISEASES 审中-公开
标题翻译： IL-10和治疗其他疾病的方法
公开(公告)号：WO2011159881A3
公开(公告)日：2012-04-12
申请号：PCT/US2011040675
申请日：2011-06-16
申请人： ALLERGAN INC , STERN MICHAEL E , SCHAUMBURG CHRISTOPHER S , SIEMASKO KARYN F , WHEELER LARRY A
发明人： STERN MICHAEL E , SCHAUMBURG CHRISTOPHER S , SIEMASKO KARYN F , WHEELER LARRY A
IPC分类号： A61K38/20 , A61K9/00 , A61P27/02
CPC分类号： C07K14/005 , A61K9/0048 , A61K38/162 , A61K38/2066 , C12N2710/24033
摘要： Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.
摘要翻译：本文公开了TPV1是通过施用IL-10和TPV134R多肽来治疗眼部和全身病症的方法。

4. 发明申请

WO9829069A2 METHOD FOR CHANGING THE REFRACTIVE POWER OF AN EYE 审中-公开
标题翻译：改变眼睛屈光力的方法
公开(公告)号：WO9829069A2
公开(公告)日：1998-07-09
申请号：PCT/US9723794
申请日：1997-12-29
申请人： ALLERGAN INC
发明人： STERN MICHAEL E , POWER DAVID F , CHEETHAM JANET K
IPC分类号： A61F9/013 , A61K38/39 , A61B3/103 , A61B3/107 , A61K31/00 , A61K31/19 , A61K31/195 , A61K31/38 , A61K31/39 , A61K31/40 , A61K31/405 , A61K31/465 , A61K31/57 , A61K31/715
CPC分类号： A61F9/013 , A61K38/39
摘要： A method provides for changing the refractive power of an eye, and includes the step of selecting a dioptic correction for an eye without compromise for regression of refractive power due to biological response to a change in corneal profile, changing the corneal profile of the eye in order to change the refractive power of the eye to the selected dioptic, (e.g. by laser of surgical procedures) and limiting regression in corneal profile due to the biological response at about to the selected diopter by applying to the corneal composition comprising an agent for controlling the biological response. The agent comprised in the composition may be a steroid, a non-steroidal anti-inflammatory agent or a basement membrane component. The change in the refractive power is intended to achieve emmetropia. The method of the present invention allows the correction of refractive/focusing disorders of the eye such as myopia, hyperopia, (a)stigmatism and so on.
摘要翻译：一种方法提供了改变眼睛屈光度的方法，并且包括以下步骤：选择用于眼睛的屈光矫正，而不会因角膜分布变化的生物反应而折射力的回归而折中，改变眼睛的角膜轮廓（例如通过外科手术的激光）来改变眼睛的屈光度，并且通过将角膜组合物应用于包含用于控制的药剂的角膜组合物，由于通过选择的屈光度的生物反应而限制角膜分布的退化生物反应。包含在组合物中的药剂可以是类固醇，非甾体抗炎剂或基底膜组分。屈光力的变化旨在实现正视。本发明的方法允许校正眼睛的屈光/聚焦障碍，例如近视，远视，（a）斑驳等。

5. 发明申请

WO2011159655A3 IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS 审中-公开
标题翻译： IL23p19用于治疗眼睛及其他症状的抗体抑制剂
公开(公告)号：WO2011159655A3
公开(公告)日：2012-04-19
申请号：PCT/US2011040274
申请日：2011-06-14
申请人： ALLERGAN INC , STERN MICHAEL E , SCHAUMBURG CHRISTOPHER
发明人： STERN MICHAEL E , SCHAUMBURG CHRISTOPHER
IPC分类号： A61K39/395 , C07K14/54 , C07K16/24
CPC分类号： C07K16/244 , A61K2039/54
摘要： Disclosed herein is a method of treating certain ocular and other diseases with an anti-IL-23p19 antibody.
摘要翻译：本文公开了一种用抗IL-23p19抗体治疗某些眼部和其它疾病的方法。

6. 发明申请

WO9316719A3 USE OF PLATELET DERIVED GROWTH FACTOR IN OPHTHALMIC WOUND HEALING 审中-公开
标题翻译：使用平板电脑衍生生长因子进行OPHTHALMIC WOUND HEALING
公开(公告)号：WO9316719A3
公开(公告)日：1993-10-28
申请号：PCT/US9301731
申请日：1993-02-24
申请人： ALLERGAN INC
发明人： STERN MICHAEL E , WHEELER LARRY A , NICOLSON MARGERY A
IPC分类号： A61K38/22 , A61K38/00 , A61K38/18 , A61P27/02 , A61P43/00 , C07K14/49 , A61K37/02 , C07K13/00
CPC分类号： C07K14/49 , A61K38/1858
摘要： A method of accelerating corneal wound healing and/or improving the quality of wound healing in a mammal comprises: (1) providing an ophthalmically compatible solution of platelet-derived growth factor; and (2) applying the solution to the cornea of a mammal at the time of or subsequent to occurrence of a corneal wound in a quantity sufficient to accelerate clinically detectable healing, the healing being accelerated through proliferation of epithelial cells and/or keratocytes of the cornea stimulated by application of the platelet-derived growth factor to the cornea. The method also improves the quality of wound healing. The platelet-derived growth factor can be selected from the group consisting of the AA isoform, the AB isoform, the BB isoform, and mixtures thereof. A preferable form of platelet-derived growth factor is a recombinantly-derived refolded B-chain homodimer of 119 amino acids, having the amino acid sequence of S-L-G-S-L-T-I-A-E-P-A-M-I-A-E-C-K-T-R-T-E-V-F-E-I-S-R-R-L-I-D-R-T-N-A-N-F-L-V-W-P-P-C-V-E-V-Q-R-C-S-G-C-C-N-N-R-N-V-Q-C-R-P-T-Q-V-Q-L-R-P-V-Q-V-R-K-I-E-I-V-R-K-K-P-I-F-K-K-A-T-V-T-L-E-D-H-L-A-C-K-C-E-T-V-A-A-A-R-P-V-T-R-S-P-G-G-S-Q-E-Q-R. The concentration of platelet-derived growth factor in the solution can be from about 10 νg/ml to about 1000 νg/ml, preferably from about 50 νg/ml to about 500 νg/ml, and most preferably about 100 νg/ml. The invention also comprises pharmaceutical compositions for application to the cornea of a mammal for accelerating corneal wound healing and/or improving the quality of wound healing and tablets for preparation of the pharmaceutical compositions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式